Skip to main content
. 2007 Dec 16;99(3):601–607. doi: 10.1111/j.1349-7006.2007.00705.x

Figure 3.

Figure 3

Binding and antibody‐dependent cellular cytotoxity (ADCC) of the seroconverted patients’ serum to HER2‐expressing tumor cells. (a) Trastuzumab, anti‐HER2 monoclonal antibody, binds to HER2‐expressing SKBR3 cells, whereas it does not react to HER2‐negative KATOIII cells. (b) Diluted serum samples of two demonstrative patients are assayed for ADCC activity against SKBR3. The cytolytic activity of trastuzumab to SKBR3 is shown as a positive control, and rituximab, anti‐CD20 monoclonal antibody, was used as a negative control.